MedKoo Cat#: 556365 | Name: OXA-06 HCl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

OXA-06 is a potent ROCK inhibitor(IC50 = 10 nM). OXA-06 suppresses pMYPT1 and pCofilin levels in non-small cell lung carcinoma (NSCLC) cell lines. OXA-06 also inhibits anchorage-independent growth of NSCLC cell lines in vitro.

Chemical Structure

OXA-06 HCl
OXA-06 HCl
CAS#1825455-91-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 556365

Name: OXA-06 HCl

CAS#: 1825455-91-1 (HCl)

Chemical Formula: C21H20Cl2FN3

Exact Mass: 0.0000

Molecular Weight: 404.31

Elemental Analysis: C, 62.39; H, 4.99; Cl, 17.54; F, 4.70; N, 10.39

Price and Availability

Size Price Availability Quantity
25mg USD 250.00 2 Weeks
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,350.00 2 Weeks
500mg USD 2,750.00 2 Weeks
1g USD 4,250.00 2 Weeks
2g USD 5,950.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1825455-91-1 (HCl) 944955-32-2 (free base)
Synonym
OXA 06 dihydrochloride; OXA-06 HCl; OXA-06; OXA 06; OXA06;
IUPAC/Chemical Name
2-Fluoro-N-[[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]methyl]benzenemethanamine dihydrochloride
InChi Key
ZRBCUSMZOWMVJS-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H18FN3.2ClH/c22-20-4-2-1-3-17(20)14-23-13-15-5-7-16(8-6-15)18-9-11-24-21-19(18)10-12-25-21;;/h1-12,23H,13-14H2,(H,24,25);2*1H
SMILES Code
FC1=CC=CC=C1CNCC2=CC=C(C3=C4C(NC=C4)=NC=C3)C=C2.[H]Cl.[H]Cl
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Evidence is emerging that the closely related ROCK1 and ROCK2 serine/threonine kinases support the invasive and metastatic growth of a spectrum of human cancer types. Therefore, inhibitors of ROCK are under preclinical development. However, a key step in their development involves the identification of genetic biomarkers that will predict ROCK inhibitor antitumor activity. One identified mechanism for ROCK activation in cancer involves the loss of function of the DLC1 tumor suppressor gene, which encodes a GTPase activating protein (RhoGAP) for the RhoA and RhoC small GTPases. DLC-1 loss may lead to hyperactivation of RhoA/C and its downstream effectors, the ROCK kinases.

Preparing Stock Solutions

The following data is based on the product molecular weight 404.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA, Dong H, Chen X, Tokar B, Campbell SL, Der CJ. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 2012 Oct 15;72(20):5338-47. doi: 10.1158/0008-5472.CAN-11-2373. Epub 2012 Aug 31. PMID: 22942252; PMCID: PMC3810962.